We read with interest the article by Capasso et al [1] and the
accompanying Editorial [2] concerning two patients with pure
motor Guillain-Barré syndrome (GBS), early nerve conduction block
(CB), preserved motor conduction velocity (MCV) and high titers of anti-
ganglioside antibodies.
They conclude that these cases may represent a
new axonal GBS variant with nerve CB induced by anti-ganglioside
antibodies. We would like to offer an alternative explanation.
Starting from current criteria for electrophysiological
classification of GBS, it seems that there is evidence of
demyelination at initial electrophysiological examinations:
1) In both
patients, MCV of ulnar nerves (above elbow-below elbow segment) less than
85% of lower limit of normal; and
2) In patient 2, distal motor latencies
(DML) of three nerves greater than 120% of upper limit of normal. [1]
It is worth noting that DML prolongation for left median nerve is not slight,
as stated by the authors, but marked (according to Figure 1D, about 6.5 ms
representing 150% of upper limit of normal). Therefore these cases should
be categorized as examples of demyelinating GBS.
The mechanism of nerve CB in GBS has not been positively established. In vitro and in vivo experimental studies indicate that
physiological action of the anti-ganglioside antibody is insufficient to
explain observed CB in human diseases. [3] In demyelinating GBS,
early and potentially reversible attenuation of CMAP with preserved MCV
may be due to an increase of endoneurial fluid pressure in nerve
trunks causing variable degrees of nerve ischemia. [4] In experimental
allergic neuritis, initial symptoms do not correlate with demyelination but
with the appearance of endoneurial edema and inflammatory infiltrates. [5]
In these cases, [1] it is conceivable that early in the
clinical course, severe focal inflammatory lesions could induce
ischemic CB in certain segments of intermediate and distal motor nerves.
Nerve ischemia in EAN or GBS mainly involves centrofascicular areas, but
substantially preserved endoneurial transverse areas remain
eventually guaranteeing maximal MCV, [4] as observed in most but not all
nerve segments examined by the authors. We agree that their
cases represent an “arrested” type of GBS possibly because of early
immunomodulatory therapy. The mechanism of selective involvement of the
motor system in GBS is puzzling as GM1 epitopes are present in motor and
sensory axons, and nerve ischemia involves motor and sensory fibers. [3,4]
References
1. Capasso M, Caporale CM, Pomilio F, Gandolfi P, Lugaresi A, Uncini A.
Acute motor conduction block neuropathy. Another Guillain-Barré syndrome
variant. Neurology 2003; 61: 617-622.
2. Yuki N, Saperstein DS. Axonal Guillain-Barré syndrome subtypes. Do we
need more splitting? Neurology 2003; 61: 598-599.
3. Kaji R, Kimura J. Facts and fallacies on anti-GM1 antibodies:
physiology of motor neuropathies. Brain 1999; 122: 797-798.
4. Berciano J, García A, Figols J, Muñoz R, Berciano MT, Lafarga M.
Perineurium contributes to axonal damage in acute inflammatory
demyelinating polyneuropathy. Neurology 2000; 55: 552-559.
5. Izumo S, Linington C, Wekerle H, Meyermann R. Morphologic study on
experimental allergic neuritis mediated by T cells line specific for
bovine P2 protein in Lewis rats. Lab Invest 1985; 53: 209-218.